Stockreport

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

AtaiBeckley Inc.  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program in [Read more]